Schizophrenia

Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.

Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993;13(6):383-90. PubMed PMID: 8120151.

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995;152(2):179-82. PubMed PMID: 7840349.

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.

Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148(2):231-5. PubMed PMID: 1670979.

Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.

Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55 Suppl B:117-21. PubMed PMID: 7961554.

Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.

Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, et al.. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacol (berl). 2000;148(1):83-9. PubMed PMID: 10663421.

Practice guideline for the treatment of patients with schizophrenia, second edition.

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56. PubMed PMID: 15000267.

Clozapine: a clinical review of adverse effects and management.

Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15(1):33-48. PubMed PMID: 12839431.

Appropriateness of therapeutic drug monitoring for lithium.

Ratanajamit C, Soorapan S, Doang-ngern T, Waenwaisart W, Suwanchavalit L, Suwansiri S, et al. Appropriateness of therapeutic drug monitoring for lithium. J Med Assoc Thai. 2006;89(11):1954-60. PubMed PMID: 17205880.

Schizophrenia.

Freedman R. Schizophrenia. N Engl J Med. 2003;349(18):1738-49. DOI: 10.1056/NEJMra035458. PubMed PMID: 14585943.

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. DOI: 10.1016/j.schres.2005.07.014. PubMed PMID: 16137860.